Table 2.
Univariable and multivariable logistic regression analyses for predicting HER2 score 3+.
| Univariable analysis | Multivariable model | |||||
|---|---|---|---|---|---|---|
| Variable | OR | 95% CI | P | OR | 95% CI | P |
| Age (per 1-year increase) | 1.01 | 1.00–1.02 | 0.015 | 1.00 | 0.99–1.01 | 0.696 |
| Female (vs. male) | 0.70 | 0.54–0.91 | 0.008 | 0.86 | 0.65–1.13 | 0.265 |
| Primary tumor location (vs. GEJ cancer) | 0.68 | 0.55–0.84 | <0.001 | 0.84 | 0.67–1.06 | 0.147 |
| Histological differentiation (vs. well) | <0.001 | <0.001 | ||||
| Moderate | 1.26 | 0.74–2.16 | 0.391 | 1.18 | 0.69–2.03 | 0.543 |
| Poor | 0.31 | 0.19–0.53 | <0.001 | 0.27 | 0.16–0.47 | <0.001 |
| Tumor size (per 1 cm increase) | 0.99 | 0.95–1.03 | 0.716 | |||
| Perineural invasion (vs. absent) | 0.91 | 0.72–1.15 | 0.442 | |||
| Lymphovascular invasion (vs. absent) | 1.07 | 0.86–1.33 | 0.523 | |||
| Examined lymph nodes (vs. ≥16) | 0.70 | 0.43–1.16 | 0.163 | |||
| T stage (vs. T1) | 0.019 | 0.164 | ||||
| T2 | 1.66 | 0.73–3.80 | 0.226 | 1.40 | 0.60–3.28 | 0.439 |
| T3 | 1.29 | 0.59–2.82 | 0.529 | 0.97 | 0.43–2.19 | 0.934 |
| T4 | 1.01 | 0.47–2.21 | 0.972 | 0.92 | 0.41–2.06 | 0.844 |
| N stage (vs. N0) | 0.169 | <0.001 | ||||
| N1 | 1.37 | 0.97–1.96 | 0.078 | 1.38 | 0.95–1.99 | 0.088 |
| N2 | 1.16 | 0.83–1.64 | 0.389 | 1.37 | 0.95–1.96 | 0.088 |
| N3 | 1.37 | 1.01–1.88 | 0.047 | 2.11 | 1.51–2.95 | <0.001 |
GEJ, gastroesophageal junction; HER2, human epidermal growth factor receptor 2; OR, odds ratio.